Pacific Biosciences of California, Inc. (PACB) Stock Score, Valuation & Financial Research
Pacific Biosciences of California, Inc. is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 11/100.
Quick answer for PACB
Pacific Biosciences of California, Inc. currently has a Wall Street Score of 11/100. The stored market price is $1.3. Its financial score is 25/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Pacific Biosciences of California, Inc. does
Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase
PACB financial snapshot
- Wall Street Score:
- 11/100
- Current price:
- $1.3
- Market capitalization:
- $403.8M
- Revenue:
- $160.0M
- Net income:
- $-128.6M
- Free cash flow:
- $-113.9M
- Cash:
- $56.3M
- Total debt:
- $703.4M
- EPS:
- -1.82
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 4/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $-113.9M, showing cash burn in the current stored period.
- The balance sheet shows $56.3M of cash versus $703.4M of total debt, so leverage deserves attention.
- The current research record carries a high debt stress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research PACB
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.